Fireside chat will be held on Wednesday, November 16, 2022, from 3:35 p.m. to 4:05 p.m. EDT
NEW
HAVEN, Conn., Nov. 8, 2022
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing an
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of serious chronic cough conditions, today announced
that Jennifer Good, President and Chief Executive Officer, and
Lisa Delfini, Chief Financial
Officer, will participate in a fireside chat at the Stifel 2022
Healthcare Conference on Wednesday, November
16, 2022, at 3:35 p.m. ET.
A live audio webcast of the fireside chat will be accessible
from the 'Investors & News' section on the Company's website
at www.TreviTherapeutics.com. An archived replay of the audio
webcast will also be available on the Company's website following
the event.
About Trevi Therapeutics,
Inc.
Trevi Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of the investigational oral therapy Haduvio™
(nalbuphine ER) for the treatment of serious chronic cough
conditions. The Company has successfully completed a Phase 2 trial
of Haduvio for the treatment of chronic cough in adults with
idiopathic pulmonary fibrosis (IPF). Based on this positive data,
Trevi plans to focus future clinical development on chronic cough
conditions, including IPF, refractory chronic cough, and
interstitial lung diseases (ILDs).
For more information, visit www.TreviTherapeutics.com and follow
the company on Twitter and LinkedIn.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-release
(ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe.
The ĸ- and µ-opioid receptors are centrally and peripherally active
and known to be critical mediators of cough and itch. Nalbuphine's
mechanism of action may also mitigate the risk of abuse associated
with µ-opioid agonists because it antagonizes, or blocks, µ-opioid
receptors. Parenteral nalbuphine is not currently scheduled as a
controlled substance by the DEA in the United States or
by regulatory authorities in most
of Europe. Trevi intends to propose Haduvio as the
trade name for nalbuphine ER. Its safety and efficacy have not been
evaluated by any regulatory authority.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-at-the-stifel-2022-healthcare-conference-301671197.html
SOURCE Trevi Therapeutics, Inc.